Dr.Shikhar Gaur, G09916
Aim: To assess the clinical outcome (s) of subconjunctival Inj bevacizumab in pterygium management where surgery is not advisable.
Method: This prospective case study included 58 patients diagnosed as pterygium. Surgery was not advisable due to early stage or unwillingness of the patient. All patients were administered with three sub conjunctival injections of 0.5 ml bevacizumab 2.5 mg/0.1 ml each at a gap of one month. Vascularity and the length of pterygia from limbus was assesed after two months of the third injection and was compared with the initial size.
Results: 51 case showed reduced vascularity at pterygium apex. Relief from irritation and itching was noted in 35 cases. Sub conjunctival haemorrhage was noted in 29 cases. No systemic complication was noted.
Conclusion: Sub conjunctival bevacizumab is effective in management of early pterygium where surgery is not the choice of modality.
PRESENTATION NOT RECEIVED FROM THE AUTHOR.
Leave a Comment